Research design and methods: 200 children and adolescents (<18 years) diagnosed with type 1 diabetes, started on multiple injection treatment and followed up for 1 year were studied with respect to metabolic control and weight change. Growth curves preceding the onset of diabetes were procured from the school health services. BMI was recalculated into BMI SD scores (BMISDS).
INTRODUCTION
At the start of treatment of newly diagnosed type 1 diabetes, there is rapid weight gain. 1 This can initially be attributed to rehydration and normalization of the acute catabolic state of untreated type 1 diabetes. There is, however, a subsequent long-term trend for continuous excessive weight gain which may be considerable during pubertal development and especially so in girls. [2] [3] [4] [5] This weight gain has repeatedly been associated with intensified insulin treatment. 4 6 When focus is on maintaining blood sugar control, weight changes may be given lower attention or even be overlooked. This is of concern since excess weight gain causes adverse changes of cardiovascular risk factors [6] [7] [8] [9] and macrovascular lesions can be detected early in life in type 1 diabetes. 10 11 At worst, overweight and increased cardiovascular risk could outweigh the beneficial effects of improved blood glucose control, cardiovascular events being a major determinant of excess mortality in type 1 diabetes. 12 In studies of the short-term outcome of type 1 diabetes in children and adolescents, good metabolic control is usually achieved 1 year after presentation but weight/body mass index (BMI) is above population average. 1 4 13-16 Premorbid weights and heights are, however, usually not available and it is unclear whether in these investigations findings represent excess weight gain during the first year of treatment or the children were constitutionally larger and heavier. At presentation of type 1 diabetes, there may be a history of overweight and increased linear growth, 17 18 but there are also several mechanisms by which type 1 diabetes and its treatment could cause excess weight gain. 19 20 The objective of the present investigation was to analyze BMI changes and metabolic control in children and adolescents with type 1 diabetes during the first year of treatment. secondary aim was to analyze whether BMI interferes with metabolic control. We hypothesized that the patients would recover their premorbid BMI trajectory early during treatment but that treatment-related factors could confer an additional risk for weight gain. 21 Data on family history of diabetes and other autoimmune diseases, weight and height of parents, symptoms and signs of type 1 diabetes at the time of diagnosis, laboratory data at diagnosis and follow-up, and details of treatment were collected and registered in the Swedish Childhood Diabetes Registry (SWEDIABKIDS), a national incidence and quality control register. 22 The diagnosis of type 1 diabetes was clinical and decided on before autoantibodies had been analyzed. The Karolinska Institute Research Ethics Board approved the study and informed, written consent was obtained from the parents.
RESEARCH DESIGN AND METHODS
The clinical diagnosis of type 1 diabetes did not have to be revised for any of the patients. One child was excluded from the analysis since the family discontinued insulin treatment for a period shortly after diagnosis. Another child with hemolytic anemia due to glucose-6-phosphate dehydrogenase deficiency was excluded from analyses including measures of glycated hemoglobin (HbA1c). From SWEDIABKIDS, basal data for each patient at the time of diagnosis of type 1 diabetes were collected. This included age, gender, comorbid diseases diagnosed before the onset of diabetes, other family members with type 1 diabetes, and immigrant background. Weight, height, blood glucose, HbA1c, blood pH, antibodies to transglutaminase IgA, thyroid peroxidase, and thyreoglobulin at the time of admission were registered. During the first year of treatment, weight, height, HbA1c, insulin dose (units/kg body weight/ day), proportion of bolus insulin (% of daily dose), and the use of insulin pump were registered at 3, 6, and 12 months duration of disease. BMI (kg/m 2 ) and BMI SD scores (BMISDS) were generated automatically by the SWEDIABKIDS register. 23 Growth charts were procured from the school health services/childcare centers.
Two measurements of weight and height antedating by at least 3 months the diagnosis of diabetes were registered. Data including growth charts antedating the diagnosis of type 1 diabetes were available for 200 (93%) patients who were included in the study.
Biochemical analyses were performed at the Department of Clinical Chemistry at the Uppsala University Hospital as part of the clinical follow-up of the patients. The laboratory is certified by a Swedish government authority (Swedac). Starting October 2010, HbA1c was analyzed according to the International Federation of Clinical Chemistry (IFCC) standard and expressed as mmol/mol. Prior to that date, analysis was according to the Mono S standard expressed in percent. In SWEDIABKIDS, analyses performed with the Mono S standard were recalculated using the expression HbA1c (IFCC; mmol/mol) =10.45×HbA1c (Mono S; %)-10.62. Presently, HbA1c is expressed in National Glycohemoglobin Standardization Program (NGSP) and IFCC standards (http://www.ngsp. org/convert1.asp).
Treatment
Treatment of type 1 diabetes was according to firmly established routines at the Uppsala University Children's Hospital and within the framework of the Swedish national programme for pediatric diabetes. 24 All patients were hospitalized at presentation. For patients with severe ketoacidosis, treatment was started at an intensive care unit. The majority of the patients were admitted to a general pediatric ward together with a parent following a brief interview, physical examination, and blood sampling. Treatment was immediately started with intravenous insulin with the aim to normalize blood sugar concentrations. Intravenous insulin was discontinued after 2-2.5 days and the patients were started on a multiple injection therapy (MIT) regime with insulin aspart (NovoRapid) added to every meal and insulin detemir (Levemir) once daily at dinner time for basal insulin. A personalized meal schedule with three daily major meals and two-three snacks was introduced. Meals were initially of a set size and with a fixed insulin dose. Families were subsequently taught to adjust doses to different meal sizes. When treating hypoglycemic episodes, measurement of blood glucose and taking dextrose is emphasized to avoid excess caloric intake. From the very onset of MIT, the aim was (near) normal blood sugar concentrations (3.5-7.5 mmol/L) and a target HbA1c<6.9% (52 mmol/mol). Families were taught that physical activity is part of treatment and children were encouraged to continue the physical activities they participated in prior to the diagnosis of diabetes.
Both parents were encouraged to take part in scheduled meetings with members of the diabetes team which consists of physicians, nurses, dieticians, and a clinical psychologist, all with training and experience in pediatric diabetes care. One aim of the training during the initial admission was to confer sufficient knowledge and practical ability to enable the families to return to their new everyday life. Another aim was to support the family and help them to meet the crisis of the abrupt and unexpected change in the family. In this context, it is notable that within the Swedish social security system parents can have reimbursed parental leave when caring for a sick child. Beginning at the end of the first week of admission and during the second week, the families were gradually transferred to home, school, and everyday life.
Following discharge from hospital after 7-15 days, a diabetes nurse was the primary contact of the family. The family attended ∼10 outpatient visits to their diabetes nurse during the first year of treatment. Other members of the diabetes team participated when required. During this first year of treatment, there was continuous diabetes education and adaptation of the treatment regime to the patients' and families' needs. Blood glucose control was emphasised and vigilance over growth and weight development was maintained. Great emphasis was put on helping the family adapt to their new family life.
Statistics
Statistical analyses were performed with SPSS V.20.0.0. Data are given as means±SD. A stepwise linear regression analysis was used for prediction of outcomes.
RESULTS
The 200 participants included in the study were at presentation of type 1 diabetes 9.3±4.4 years old, 58% were male, 15% had at least one parent not born in Sweden, and 11.5% had type 1 diabetes in the primary family (table 1) . Eight had celiac disease and four had hypothyreosis diagnosed prior to the onset of type 1 diabetes. At diagnosis, HbA1c was 10.8±2.6 (95±23 mmol/ mol) and 22.8% had diabetic ketoacidosis (defined as pH<7.3; table 1).
Three months after diagnosis, HbA1c had decreased to 6.2%±1.1 (44±8 mmol/mol; figure 1A) . HbA1c increased to 6.7±1.3% (50±10 mmol/mol; p<0.001 by one-sided analysis of variance) up to the 1 year follow-up. Treatment at 1 year was usually by MIT; only nine children used an insulin pump. Three months after diagnosis, the mean daily insulin dose was 0.69±0.20 units/ kg/day. At 6 months, it was 0.72±0.2 units/kg/day, and at 1 year follow-up it had increased to 0.81±0.24 units/kg/ day ( p<0.001). At 1 year, 53±11% of the insulin dose was taken as a meal bolus; this proportion had not changed over the first year (table 2) . A further 12 patients had been diagnosed with celiac disease and 3 with hypothyreosis during the first year of treatment. Patients with these comorbidities did not differ in the BMISDS or HbA1c at 1 year. There were no episodes of diabetic ketoacidosis and no episodes of severe hypoglycemia with unconsciousness or seizures. Analysis of the growth charts from the school health services provided two measurements of BMISDS 1.5±1.5 and 3.1±1.9 years before the presentation of type 1 diabetes. The BMISDS was then 0.33±1.21 and 0.41±1.20, respectively (figure 1B). At presentation, BMISDS had decreased to −0.63±1.25 ( p<0.001). Following start of treatment, lost weight was recovered and already at 3 months BMISDS was 0.54±0.97, close to the premorbid level. BMISDS remained at this level up to the 1 year follow-up. This was not significantly different from the premorbid values ( p>0.05).
In a bivariate regression, BMISDS at 1 year was directly proportional to and highly predicted by BMISDS measured at the point closest prior to onset of type 1 diabetes (R 2 =0.54; p<0.001; figure 2 ). When BMISDS at 1 year was entered as the dependent variable in a stepwise linear regression analysis, it was positively predicted by BMISDS prior to onset (R 2 =0.57; p<0.001) and inversely by age (R 2 =0.03; p<0.001) but not by gender, insulin dose, percent bolus insulin, HbA1c at 1 year, or by HbA1c and pH at presentation. Analysis of the residuals did not indicate a curvilinear relationship between BMISDS prior to onset of type 1 diabetes and at 1 year follow-up ( figure 2) .
In a similar analysis, HbA1c at 1 year was positively predicted by the daily insulin dose at 1 year (R 2 =0.13; p<0.001), inversely by age (R 2 =0.12; p<0.001), and inversely by pH at presentation (R 2 =0.02; p<0.05) but not by gender, BMISDS at 1 year, or by BMISDS and HbA1c at presentation.
CONCLUSION
This study shows that it is possible to achieve good metabolic control without excess weight gain in children and adolescents with recently diagnosed type 1 diabetes. It is well established that following start of insulin treatment there is initially rapid weight gain but that the increase of BMI levels off after the first few weeks/ months. 1 14 15 25 26 Using objective growth data obtained prior to the onset of type 1 diabetes, it was possible to confirm the hypothesis that a stable BMISDS plateau is reached at the premorbid BMI trajectory without an upward trend suggesting future overweight. BMISDS was, however, above population average (ie, BMISDS>0) already prior to the onset of type 1 diabetes, in line with previous observations of a growth (rate) and BMI above average. 15 17 18 BMISDS at 1 year was highly predictable by the premorbid BMISDS but not to any large extent by other factors. In this context, it is notable that the relationship between BMISDS before onset of type 1 diabetes and at the 1 year follow-up was strictly linear, that is, there was no tendency for the more obese to overshoot their premorbid trajectory. Neither was there a tendency for the previously demonstrated excess weight gain in girls 2 3 27-30 or with increasing age and pubertal development. 3 28 30 Altogether, this would suggest that BMISDS 1 year after the diagnosis of type 1 diabetes is to a large extent determined by hereditary factors 31 and represents 'tracking', or following a predetermined developmental trajectory. Type 1 diabetes itself and its treatment can influence growth and development and cause excess weight gain. 19 Presently, the disease-related and treatment-related factors investigated had little predictive value. Some aspects of the treatment regime presently endorsed could have helped to avoid excessive weight gain. The use of insulin detemir as basal insulin has been shown to promote stable weight compared with other basal insulins. 32 The use of dextrose rather than foods for treatment of hypoglycemia limits excess energy intake at such occasions. Starting dietary Figure 2 Correlation between BMI SD score prior to the onset of diabetes and at 1 year follow-up in 200 children and adolescents. The correlation is highly significant (R 2 =0.54; p<0.001). BMISDS, body mass index SD score.
treatment with basal carbohydrate counting and set meals decreases flexibility in food choice but maintains focus on both glycemic control and energy intake/ dietary quality. There is indeed some evidence to indicate that the full flexibility of advanced carbohydrate counting may promote weight gain even if blood glucose control is maintained. 33 34 Moreover, during the first year of treatment, the patients can be expected to have residual insulin production. This is delivered in the portal vein system, inhibits hepatic lipolysis better than peripherally administered insulin, and may cause less peripheral fat deposition. 35 Altogether, these mechanisms can help to avoid unwanted weight gain. To this should be added that during the first year with type 1 diabetes the families are likely to adhere closely to the treatment regime. Treatment-related effects on BMI may therefore become apparent only later when adolescents/families develop their own course of lifestyle and diabetes management. 36 The HbA1c level presently achieved at the 1 year follow-up compares favorably with previous studies. It was also confirmed that the nadir of HbA1c is reached early in the course of treatment, in this case at the 3-month control. There is subsequently a slow increase up to the 1 year control. 1 16 25 26 37 This is not to say that metabolic control is lost since HbA1c still mirrors an ability to handle treatment well. It may rather reflect a successive loss of remaining endogenous insulin and a consequent increase in blood glucose excursions. The relationship between HbA1c and insulin dose at the 1 year control would also reflect this loss of endogenous insulin production. The association between higher HbA1c and lower age probably reflects the difficulties of achieving optimal blood glucose control in small children who also have a more rapid decline of their own remaining endogenous insulin production. 25 Metabolic decompensation at presentation, as evidenced by low pH, was weakly related to HbA1c at 1 year as previously shown, 16 25 37 although a parallel association with high HbA1c at presentation could not be demonstrated. The effect sizes, as evidenced by the R 2 contributions, were low and only little of the variation of HbA1c was explained by these factors. It is more notable that female gender and weight/BMI, which are related to increasing HbA1c in longitudinal, long-term studies, 2 28 29 38 were not related to HbA1c at the present 1 year follow-up. It may be that in the absence of such a gender-related and age-related weight gain, the increase with time of HbA1c is attenuated. This emphasizes the need to carefully monitor weight (changes), and not just blood glucose control, during the initial treatment of type 1 diabetes. Since weight gain inevitably depends on what is eaten, nutritional education of the family from the very start is thus essential. 5 A strength of this study is the analysis of a large number of patients, treated at a single unit with a uniform treatment programme which has changed little over time and has an ambitious treatment target. 39 There is a limitation in that some possible predictors of metabolic control and weight changes such as physical activity, Tanner staging of puberty, and measurements of C peptide were not available. These limitations, however, do not preclude the major conclusion of the absence of excess weight gain.
In conclusion, with the aid of growth charts from the school health services providing premorbid growth data, it was possible to demonstrate excellent metabolic control without excess weight gain 1 year after presentation of type 1 diabetes. The absence of excess weight gain may help to avoid early deterioration of cardiovascular risk factors. In the light of other longitudinal studies that have shown a successive increase of HbA1c with time concomitant with an excessive weight gain it would be important to extent the present study with a longer term follow-up.
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